0001062993-22-012388.txt : 20220513 0001062993-22-012388.hdr.sgml : 20220513 20220513164353 ACCESSION NUMBER: 0001062993-22-012388 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220512 FILED AS OF DATE: 20220513 DATE AS OF CHANGE: 20220513 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Van Strydonck, Gerald E. CENTRAL INDEX KEY: 0001748247 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38624 FILM NUMBER: 22923507 MAIL ADDRESS: STREET 1: 1895 MOUNT HOPE AVENUE CITY: ROCHESTER STATE: NY ZIP: 14620 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VACCINEX, INC. CENTRAL INDEX KEY: 0001205922 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 161603202 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1895 MOUNT HOPE AVE CITY: ROCHESTER STATE: NY ZIP: 14620 BUSINESS PHONE: 585-271-2700 MAIL ADDRESS: STREET 1: 1895 MOUNT HOPE AVE CITY: ROCHESTER STATE: NY ZIP: 14620 FORMER COMPANY: FORMER CONFORMED NAME: VACCINEX INC DATE OF NAME CHANGE: 20021114 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2022-05-12 0001205922 VACCINEX, INC. VCNX 0001748247 Van Strydonck, Gerald E. C/O VACCINEX, INC. 1895 MOUNT HOPE AVENUE ROCHESTER NY 14620 1 0 0 0 Common Stock 20000 D Stock Option (Right to Buy) 14.90 2023-03-06 Common Stock 7500 7500 D Stock Option (Right to Buy) 13.60 2027-09-15 Common Stock 6396 6396 D Stock Option (Right to Buy) 5.26 2029-03-30 Common Stock 2501 2501 D Stock Option (Right to Buy) 7.78 2020-05-15 Common Stock 7718 7718 D Stock Option (Right to Buy) 5.52 2029-06-29 Common Stock 2385 2385 D Stock Option (Right to Buy) 7.17 2029-09-27 Common Stock 1856 1856 D Stock Option (Right to Buy) 4.85 2029-12-28 Common Stock 2737 2737 D Stock Option (Right to Buy) 3.95 2021-05-14 Common Stock 15679 15679 D Stock Option (Right to Buy) 2.15 2022-05-11 Common Stock 28586 28586 D Stock Option (Right to Buy) 1.12 2022-05-12 4 A 0 53254 0 A 2023-05-12 Common Stock 53254 53254 D Exercisable in full as of the date of this report. This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first. This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first. This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first. /s/ Scott E. Royer, Attorney-in-Fact for Gerald E. Van Strydonck 2022-05-13